Vielanin P Enhances the Cytotoxicity of Doxorubicin Via the Inhibition of PI3K/Nrf2-stimulated MRP1 Expression in MCF-7 and K562 DOX-resistant Cell Lines.

Gao Hong-Liang,Xia Yuan-Zheng,Zhang Ya-Long,Yang Lei,Kong Ling-Yi
DOI: https://doi.org/10.1016/j.phymed.2019.152885
IF: 6.656
2019-01-01
Phytomedicine
Abstract:Background: Cancer cells that are resistant to structurally and mechanically unrelated anticancer drugs are said to have multidrug resistance (MDR). The overexpression of the ATP-binding cassette (ABC) transporter is one of the most important mechanisms of MDR. Vielanin P (VP), a dimeric guaiane from the leaves of Xylopia vielana, has the potential to reverse multidrug resistance. Purpose: To evaluate the meroterpenoid compound VP as a low cytotoxicity MDR regulator and the related mechanisms. Methods: Cell viability was determined by CCK-8 and MTT assays. Apoptosis and the accumulation of doxorubicin (DOX) and 5(6)-carboxyfluorescein diacetate (CFDA) were determined by flow cytometry. We determined mRNA levels by quantitative real-time polymerase chain reaction (qRT-PCR). Protein levels were analyzed by Western blotting and immunofluorescence. Results: In the MCF-7 and K562 DOX-resistant cell lines, VP treatment (10 mu M or 20 mu M) enhanced the activity of chemotherapeutic agents. We found that VP selectively inhibited MRP1 mRNA but not MDR1 mRNA. VP enhanced DOX-induced apoptosis and reduced colony formation in the presence of DOX in drug-resistant cells. Moreover, VP increased the accumulation of DOX and the MRP1-specific substrate CFDA. In addition, VP reversed MRP1 protein levels and the accumulation of DOX and CFDA in MRP1-overexpressing MCF-7 and K562 cells. Thus, the mechanism of MDR reversal by VP is MRP1-dependent. Furthermore, we found that the inhibitory effect of VP on MRP1 is PI3K/Nrf2-dependent. Conclusion: These results support the potential therapeutic value of VP as an MDR-reversal agent by inhibiting MRP1 via PI3K/Nrf2 signaling.
What problem does this paper attempt to address?